GLYcoDiag specialize in glycosciences and microbiology products and services. We help industrial clients since 2005 to boost innovation and rapid ingredient development for human and animal health, cosmetics, nutraceuticals and environment.

BioAZ develops innovative immunotherapies for animal health. Founded in 2022 by a veterinarian, the French biotech meets unmet needs in pets and livestock, with ethical and sustainable solutions that support the agroecological transition.

CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos’ CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate.